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ABSTRACT 
We report here a serendipitous observation of marked variations in blood thrombocyte count 
without agranulocytosis in a patient being treated with clozapine. Possible mechanisms of this 
thrombocytopenia and thrombocytosis related to clozapine are discussed, raising questions 
regarding monitoring of platelet counts alongwith granulocyte counts to prevent serious complica-
tions as a result of thrombocytosis or thrombocytopenia. 
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Clozapine, is an effective antipsychotic 
drug having potential benefit in patients refrac-
tory to the typical antipsychotic drugs (Kane et 
al., 1988). But its usage had been limited by its 
potentially life threatening side effects like 
granulocytopenia. Intensive precautionary 
monitoring of white blood cell total and differ-
ential counts at regular intervals have been 
introduced. However, platelet counts in patients 
receiving clozapine are not monitored. We 
herein report a case with marked variations in 
platelet counts while on treatment with 
clozapine. 
CASE REPORT 
Mr. A, age 19 years, single, student 
presented in December 1993 to National 
Institute of Mental Health and Neurosciences, 
Bangalore, with a 15 month history of social 
withdrawal, decreased personal care, 
disturbances in sleep and appetite and a 
history suggestive of catatonic symptoms. He 
had a past history of measles at the age of 5 
years. Psychiatric examination revealed cata-
tonic signs in the form of mutism and active 
negativism, lasting a week. Subsequently, 
delusions of reference and persecution, and first 
rank symptoms were elicited. A diagnosis of 
Paranoid Schizophrenia was made according 
to the International Classification of Diseases-
10 (ICD-10, World Health Organisation, 1990). 
He was treated with trifluoperazine (20 mg/day) 
and had good clinical improvement for a year 
and half when he discontinued medication and 
had a relapse. On restarting trifluoperazine (20 
mg/day), patient developed severe EPS and 
did not show improvement in his psychiatric 
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symptoms for 8 weeks. Patient was then started 
on clozapine (25 mg/day). Baseline haemo-
"* gram, White Blood Cell Tota' Count (TC) and 
Differential Count (DC) were within normal 
limits. The dose of clozapine was gradually 
increased to 200 mg/day over a period of one 
month when the weekly haemogram remained 
within normal limits. Observations are available 
upto 38 weeks of treatment with clozapine. 
Total leucocyte count remained within normal 
limits of 5000 to 10,400 cells/cumm through-
out, although fluctuations were observed, as 
shown in the graph (Fig. 1). 
The patient's father inadvertently got 
platelet counts done. Platelet count showed 
marked variation. There was a gradual decrease 
from 16th week onwards reaching 45,450 cells/ 
cumm (normal range 1.5-4 lakh/cumm.) by 24th 
week. Clozapine was stopped for a week and 
then restarted. By week 26, thrombocytosis with 
a count of 7,07,000 cells/cumm was noted. 
Patient had no evidence of inflammation, bleed-
ing purpura, petechiae, tumour or iron defi-
ciency. Platelet counts dipped to 1,00,000/ 
cumm by weeks 28 to 30 which again rose to 
6,56,500/cumm by week 36 on clozapine 150 
mg/day. Bleeding time (1'50") Clotting time 
(5'45") and Prothrombin time (20", control 15") 
were within normal limits. There was no 
evidence of bleeding or thrombosis. However, 
the patient showed remarkable clinical improve-
ment on clozapine 200 mg/day which has 
continued to date (37.5 mg/day). No further 
fluctuations have been noticed in the platelet 
counts since the last 15 months. The figure 1 
gives a graphic representation of the platelet 
and white cell counts during the 38 weeks of 
treatment on clozapine. 
DISCUSSION 
In this case, monitoring of platelet counts 
was initially not advised, but was being done 
incidentally by the laboratory. On noticing the 
reduction in platelet counts for the first time, 
we advised the patient to have the platelet 
counts monitored regularly. Observations 
indicate that: (i) thrombocytopenia has occurred 
at doses of 200 mg/day which has ceased on 
either stopping the drug or reducing the dose 
to 150 mg/day; (ii) Thrombocytopenia was fol-
lowed by thrombocytosis on the two occasions; 
(iii) There was no relationship between 
variations in platelet count and leucocyte count. 
Regarding the possible mechanism of 
this observation, the first issue is whether the 
varying platelet counts are dose related. The 
significant change in platelet count was seen 
even with variation of clozapine dose by 50 mg/ 
day. Hence it is difficult to conclude whether 
thrombocytopenia is dose related. Secondly, 
drug induced thrombocytopenia may occur ei-
ther due to direct toxic effect of the drug on the 
marrow as an idiosyncratic reaction or due to a 
hypersensitivity reaction leading to excess de-
struction. The destruction of platelets stimulates 
production of platelets (Penington, 1984). This 
may explain thrombocytosis following throm-
bocytopenia on the two occasions. On the other 
hand, thrombocytosis may also be due to the 
direct effect of clozapine on the marrow. Thirdly, 
as shown in the graph (figure 1), total leuco-
cyte count remained within normal limits. There 
does not seem to be a correlation between the 
variation in platelet counts and total leucocyte 
count. This raises the question whether the 
factors causing neutropenia/agranulocytosis 
and thrombocytosis are similar or different. 
Focusing onto the consequences of 
thrombocytosis/thrombocytopenia, the effects 
may be benign as in this case or potentially le-
thal. Thrombocytopenia with a platelet count 
between 50,000 to 1,00,000/cu.mm causes mild 
prolongation of bleeding time. Platelet counts 
below 50,000/cumm. manifest with skin 
purpura on minor trauma and bleeding in the 
mucous membrane after surgery. Spontaneous 
bleeding, petechiae, ecchymoses, and 
hematomas occur when platelet counts drop 
below 20,000/cumm and can be fatal. 
Menorrhagia is a serious problem in women with 
thrombocytopenia. Thrombocytosis may be 
benign when it is secondary to cell destruction. 
However thrombocytosis may also lead to 
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either severe bleeding or thrombosis, which 
may be fatal (Penington, 1984). In a case 
report, clozapine related thrombocytopenia 
resulted in epistaxis (Durst et al., 1993). 
The reviews on haematological side 
effects of clozapine are silent about platelet 
counts. There was just a single mention of 
thrombocytopenia. A review of database from 
the CPMS (Clozaril Patient Monitoring 
Service) of UK and Ireland showed that 4.3% 
of patients had to stop clozapine due to 
haematological reasons. Of 6316 patients, there 
were 182 cases of neutropenia, 48 of agranulo-
cytosis, 38 of leucopenia and 6 of thrombocy-
topenia (Atkin et al., 1996). The authors have 
not discussed whether the thrombocytopenia 
occurred in those with other haematological 
abnormalities or the consequences of the same. 
Our case raises the question about the 
need to monitor platelet count regularly during 
treatment with clozapine. There is a need for 
research to answer several questions in this 
regard. What is the incidence of thrombocyto-
penia/thrombocytosis? What is the mechanism 
by which clozapine causes this adverse effect? 
What is its relationship to neutropenia/agranu-
locytosis? Is the platelet variation due to 
clozapine benign/lethal? How long and at what 
intervals is monitoring of platelet counts 
necessary? Nevertheless, this report draws 
attention towards the significance of platelet 
counts in patients receiving clozapine. 
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